biostudies-literatureGillam-Krakauer MNCATS NIH HHSFoundation for the National Institutes of HealthNHLBI NIH HHSFoundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)109-118https://www.ebi.ac.uk/biostudies/studies/S-EPMC7499931biostudies-literatureUnknown41(1)<h4>Background</h4>Prophylactic indomethacin (3 doses) decreases patent ductus arteriosus (PDA) and intraventricular hemorrhage (IVH) in preterm infants. The study aim was to determine whether single-dose indomethacin (SD-INDO) decreases PDA, IVH, and improves motor function.<h4>Methods</h4>A retrospective cohort (2007-2014) compared infants born < 29 weeks who did (n = 299) or did not (n = 85) receive SD-INDO and estimated outcomes association with ordinal logistic regression, adjusting for multiple variables using propensity scores.<h4>Results</h4>Infants who received SD-INDO were more premature (p < 0.001) but had lower odds of PDA (OR 0.26 [0.15, 0.44], p < 0.005), PDA receiving treatment (OR 0.12 [0.03, 0.47], p < 0.005), death (OR 0.41 [0.20, 0.86], p = 0.02), and CP severity (OR 0.33 [0.12, 0.89], p = 0.03). There was less IVH (OR 0.58 [0.36, 0.94], p = 0.03) when adjusted for gestational age.<h4>Conclusions</h4>SD-INDO is associated with decreased PDA and CP severity and improved survival.Journal of perinatology : official journal of the California Perinatal AssociationOutcomes in infants < 29 weeks of gestation following single-dose prophylactic indomethacin.PMC7499931R01 HL128386R01 HL109199UL1 TR000445HL 109199Maitre NLGillam-Krakauer MSlaughter JCReese JCotton RBRobinson BEfalseOutcomes in infants < 29 weeks of gestation following single-dose prophylactic indomethacin.<h4>Background</h4>Prophylactic indomethacin (3 doses) decreases patent ductus arteriosus (PDA) and intraventricular hemorrhage (IVH) in preterm infants. The study aim was to determine whether single-dose indomethacin (SD-INDO) decreases PDA, IVH, and improves motor function.<h4>Methods</h4>A retrospective cohort (2007-2014) compared infants born < 29 weeks who did (n = 299) or did not (n = 85) receive SD-INDO and estimated outcomes association with ordinal logistic regression, adjusting for multiple variables using propensity scores.<h4>Results</h4>Infants who received SD-INDO were more premature (p < 0.001) but had lower odds of PDA (OR 0.26 [0.15, 0.44], p < 0.005), PDA receiving treatment (OR 0.12 [0.03, 0.47], p < 0.005), death (OR 0.41 [0.20, 0.86], p = 0.02), and CP severity (OR 0.33 [0.12, 0.89], p = 0.03). There was less IVH (OR 0.58 [0.36, 0.94], p = 0.03) when adjusted for gestational age.<h4>Conclusions</h4>SD-INDO is associated with decreased PDA and CP severity and improved survival.2021-01-01T00:00:00Z2021 Jan2024-11-21T03:56:23.945Z2020-09-25T07:04:18ZS-EPMC74999313294881410.1038/s41372-020-00814-9